Healthcare · NYSE/NASDAQ: AZN
ASTRAZENECA PLC
Drug Manufacturers - General
Market Cap $274.92B
Verdict: High
Quality Scores
Multi-Bagger
74/100
Compounder Quality
86/100
Management Credibility
90/100
Governance
88/100
Cash Flow Quality
85/100
AI Summary
AstraZeneca has undergone a significant transformation over the last decade, evolving from a company facing a massive 'patent cliff' to a global leader in Oncology, Rare Disease, and Biopharmaceuticals. The 2021 acquisition of Alexion Pharmaceuticals fundamentally shifted the company's profile toward high-margin, rare disease therapies, diversifying revenue away from primary care. Revenue growth has accelerated into the double digits recently, driven by blockbuster assets like Tagrisso, Imfinzi, and Farxiga. While debt levels increased to fund the Alexion acquisition, the company's strong R&D…
Top Opportunities
- Leader in Oncology (Tagrisso, Imfinzi, Lynparza)
- Strategic diversification into Rare Disease via Alexion
- Strong emerging markets presence (notably China)
Top Risks
- Significant litigation risk (Zantac and others)
- Heavy reliance on a few blockbuster drugs
- Rising net debt profile over the decade
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.